Applications of 1-(2-Pyrimidinyl)Piperidine-4-Carboxylic Acid in Industrial Manufacturing

As a specialized producer of 1-(2-Pyrimidinyl)Piperidine-4-Carboxylic Acid, we supply this advanced heterocyclic intermediate directly to a range of pharmaceutical and agricultural chemical manufacturers. Stringent quality management ensures suitability for use in tightly controlled synthesis processes across multiple verticals. Below, we detail real industrial use cases with practical specification and integration guidance.

1. Antipsychotic & Central Nervous System (CNS) Pharmaceutical Synthesis

Major pharmaceutical manufacturers commonly use this pyrimidine-piperidine derivative in multi-step synthesis of second-generation antipsychotic drug substances. During key heterocyclic ring-building stages, it introduces unique structural motifs critical for receptor-binding affinity and metabolic stability. Production is oriented around regulatory filings, scale-up batch consistency, and reproducibility for regulated APIs.

Industry compliance standards

• ICH Q7 – Good Manufacturing Practice for Active Pharmaceutical Ingredients
• United States Pharmacopeia (USP) General Chapter <795>
• European Pharmacopoeia (Ph. Eur.) monographs relevant to CNS agents
• US FDA cGMP (21 CFR Part 210/211)

Typical usage ratio

• Employed at 0.15-0.35 molar equivalents relative to the final API; precise amount depends on the target molecule’s substitution pattern and yield optimization study outcomes

Downstream process integration

• Incorporated at the heterocyclic ring coupling stage through amide or peptide coupling methodologies, often via EDCI or carbodiimide-mediated reactions, followed by in-process controls (LC/MS, HPLC)

Final product types

• Finished antipsychotic therapeutics (oral tablets, injectable formulations)
• Intermediates for CNS disorder therapies
• Regulatory filing-grade APIs

2. Active Ingredient Synthesis for Selective Herbicides

Leading agrochemical companies integrate this functionalized carboxylic acid into the synthesis route of pyrimidine-based herbicide actives. By introducing a unique nitrogen framework, they achieve selective inhibition of key plant enzymes, supporting desired crop safety profiles and field stability throughout the product lifecycle.

Industry compliance standards

• FAO Specification for Plant Protection Products
• OECD Guidelines for the Testing of Chemicals (Synthesis and Quality)
• ISO 9001:2015-certified production environments
• REACH registration for raw material sourcing

Typical usage ratio

• Concentration in the synthetic step: 0.2-0.5 molar equivalents relative to final active; adjusted based on precursor reactivity and downstream mineralization requirements

Downstream process integration

• Feeding into controlled N-alkylation or cyclization stages; subsequent purification through crystallization or preparative HPLC to achieve regulatory residue standards

Final product types

• Pyrimidine-containing herbicide technical active ingredients
• Granular or emulsifiable herbicide formulations
• Pre-mix concentrate herbicidal solutions

3. Intermediate for Antiviral Drug Manufacture

This raw material serves as a key intermediate for synthesizing nucleoside analogues and other antiviral agents targeting RNA polymerase or protease pathways. Its distinctive piperidine backbone enables creation of structural analogs with improved pharmacokinetic profiles, supporting production for regulated markets requiring batch-to-batch consistency and in-depth analytical validation.

Industry compliance standards

• WHO GMP for Pharmaceutical Products
• Chinese Pharmacopoeia (ChP) for intermediates
• US FDA DMF submission practices
• EMA Guidelines on Good Distribution Practice (GDP)

Typical usage ratio

• Generally 0.05-0.18 molar equivalents, optimized through route scouting studies to balance cost, throughput, and impurity control

Downstream process integration

• Added in the mid-stage synthesis for nucleoside side chain assembly, using controlled pH and temperature for selective activation; subject to continuous in-process QC (GC/HPLC purity test, NMR identity check)

Final product types

• Bulk antiviral API intermediates
• Finished antiviral therapeutic agents
• Clinical trial active compounds

4. Synthesis of Novel Analgesic Agents

Pharmaceutical innovators use this scaffold to develop pipeline NCEs (New Chemical Entities) with analgesic and anti-inflammatory potential, leveraging its ability to stabilize heteroaromatic pharmacophores for modulation of pain pathways. Emphasis is on scalable reaction conditions with robust impurity profile management for early- and late-phase clinical manufacturing.

Industry compliance standards

• cGMP for Investigational Medicinal Products (IMPs)
• EU EMA Guideline on Process Validation
• ISO 14644-1:2015 (cleanroom standards for pilot plant synthesis)
• QMS based on ICH Q10

Typical usage ratio

• Between 0.08–0.35 equivalents, determined by structure-activity optimization and impurity threshold studies; adjusted per process scale and regulatory submission needs

Downstream process integration

• Charged during the scaffolding phase for heterocycle construction, then advanced through amide coupling or cyclocondensation; controlled temperature and solvent conditions minimize byproduct generation

Final product types

• API intermediates for analgesic NCEs
• Finished non-opioid analgesic formulations
• Clinical research reference compounds

5. Building Block for Advanced Research Reagents

Contract R&D laboratories and research reagent manufacturers incorporate this intermediate as a core building block for custom molecule design, bioconjugation projects, and small-molecule probe synthesis. Its defined purity and functionalizable carboxyl group allow precision derivatization, supporting reproducible high-purity output for biomedical research.

Industry compliance standards

• ISO 9001:2015 (quality management for research chemical production)
• GLP (Good Laboratory Practice) for process documentation
• Institutional Material Transfer Agreement (MTA) traceability
• Sigma-Aldrich procedural standards for research chemical quality (as reference specification level)

Typical usage ratio

• Routinely 0.02–0.12 equivalents per reaction, modified in response to target derivative complexity and functionalization yield goals

Downstream process integration

• Added at the initiation step for solid-phase or solution-phase synthesis of custom analogues; in-line monitoring for reaction completeness using NMR or mass spectrometry

Final product types

• Functionalized chemical tool compounds
• Bioconjugated diagnostic reagents
• Reference standards and labeling agents